ProtoKinetix Inc. (PKTX.OB) Adds New Board Member

2/26/2015 11:52:08 AM

VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCQB:PKTX) (www.protokinetix.com) today announced that Peter K. Jensen, LL.B., BCL, B.Sc., Chairman of RepliCel Life Sciences and practicing lawyer, was appointed to the company's board of directors. The Company has also issued 1,000,000 shares of common stock of the Company and a three-year option for 1,000,000 shares of common stock exercisable at $0.05US per share to Mr. Jensen in connection with his appointment to the Board and for services to the Company.

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.